Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
-
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
-
Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansionContinued advancement of pharmaceutical pipeline, medical affairs initiatives and international...
-
TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
-
TORONTO, May 01, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
-
Rescheduling aligns with Avicanna’s established pharmaceutical and medical cannabis strategyRescheduling further supports advancement of R&D, clinical development, and medical affairs initiatives ...
-
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
-
An established forum for evidence-based clinical discussion, interdisciplinary dialogue, and patient considerationsEvent is expanded to two days, live and virtual on June 11-12, 2026, at the MaRS...
-
TORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing...
-
Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full year Advancements across business units, R&D, and clinical development to support scale and...